600594 益佰制药
已收盘 04-14 15:00:00
资讯
新帖
简况
4月13日益佰制药(600594)龙虎榜数据
证券之星 · 04-13 17:14
4月13日益佰制药(600594)龙虎榜数据
每周股票复盘:益佰制药(600594)近5日4次登龙虎榜
证券之星 · 04-12 01:09
每周股票复盘:益佰制药(600594)近5日4次登龙虎榜
4月9日益佰制药(600594)涨停分析:新药获批、成本优化驱动
证券之星 · 04-09
4月9日益佰制药(600594)涨停分析:新药获批、成本优化驱动
股市必读:益佰制药(600594)4月8日收盘跌8.18%,主力净流出701.79万元
证券之星 · 04-09
股市必读:益佰制药(600594)4月8日收盘跌8.18%,主力净流出701.79万元
4月7日益佰制药(600594)龙虎榜数据
证券之星 · 04-07
4月7日益佰制药(600594)龙虎榜数据
每周股票复盘:益佰制药(600594)近5日3次登上龙虎榜
证券之星 · 04-05
每周股票复盘:益佰制药(600594)近5日3次登上龙虎榜
益佰制药(600594)披露股票交易异常波动公告,4月3日股价下跌2.08%
中金财经 · 04-03
益佰制药(600594)披露股票交易异常波动公告,4月3日股价下跌2.08%
BD+业绩双重炸裂,创新药多股涨停,黄金窗口期来了?
格隆汇 · 04-02
BD+业绩双重炸裂,创新药多股涨停,黄金窗口期来了?
异动快报:益佰制药(600594)4月2日10点28分触及涨停板
证券之星 · 04-02
异动快报:益佰制药(600594)4月2日10点28分触及涨停板
4月1日益佰制药(600594)龙虎榜数据
证券之星 · 04-01
4月1日益佰制药(600594)龙虎榜数据
益佰制药(600594)披露获得注射用阿扎胞苷药品注册证书,3月30日股价上涨2.34%
证券之星 · 03-30
益佰制药(600594)披露获得注射用阿扎胞苷药品注册证书,3月30日股价上涨2.34%
益佰制药最新公告:获得注射用阿扎胞苷药品注册证书
证券之星 · 03-27
益佰制药最新公告:获得注射用阿扎胞苷药品注册证书
股市必读:益佰制药(600594)3月23日收盘跌6.25%,主力净流出64.74万元
证券之星 · 03-24
股市必读:益佰制药(600594)3月23日收盘跌6.25%,主力净流出64.74万元
每周股票复盘:益佰制药(600594)预计2025年扣非净亏损2.8亿至3.36亿元
证券之星 · 01-25
每周股票复盘:益佰制药(600594)预计2025年扣非净亏损2.8亿至3.36亿元
益佰制药最新公告:预计2025年净利润亏损2.85亿元-3.42亿元
证券之星 · 01-21
益佰制药最新公告:预计2025年净利润亏损2.85亿元-3.42亿元
每周股票复盘:益佰制药(600594)预计2025年净利为负
证券之星 · 01-18
每周股票复盘:益佰制药(600594)预计2025年净利为负
益佰制药:预计2025年全年归属净利润为负值,公司2025年度经营业绩将出现亏损
证券之星 · 01-12
益佰制药:预计2025年全年归属净利润为负值,公司2025年度经营业绩将出现亏损
益佰制药(600594)披露年度审计机构变更签字注册会计师公告,12月08日股价下跌1.41%
证券之星 · 2025-12-08
益佰制药(600594)披露年度审计机构变更签字注册会计师公告,12月08日股价下跌1.41%
益佰制药(600594)股东窦启玲质押2100万股,占总股本2.65%
证券之星 · 2025-11-27
益佰制药(600594)股东窦启玲质押2100万股,占总股本2.65%
益佰制药(600594)披露增补公司独立董事议案获通过,11月26日股价上涨1.93%
证券之星 · 2025-11-26
益佰制药(600594)披露增补公司独立董事议案获通过,11月26日股价上涨1.93%
公司概况
公司名称:
贵州益佰制药股份有限公司
所属行业:
医药制造业
上市日期:
2004-03-23
主营业务:
贵州益佰制药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用洛铂、银杏达莫注射液、复方斑蝥胶囊、艾愈胶囊、心脉通胶囊、理气活血滴丸、丹灯通脑滴丸、疏肝益阳胶囊、妇炎消胶囊、葆宫止血颗粒、妇科调经滴丸、岩鹿乳康片、金莲清热泡腾片、金骨莲胶囊、心胃止痛胶囊、注射用瑞替普酶、科博肽。曾获得“中国医药制造业百强”称号、“中国AAA级信用企业”、“贵州省劳动关系和谐企业”、“中国大健康产业突出贡献奖”、“中国西部企业数字化转型优秀实践单位”、“年度品牌卓越企业”、“贵州企业100强”、“贵州省民营企业100强”、“贵州制造业企业100强”、“中华民族医药百强品牌企业”、“中国企业信用500强”、“贵州省制造业民营企业20强”、“中国医药工业百强企业”、“中国医药研发产业线最佳工业企业”、“中国医药工业最具投资价值企业”、“贵州省促进新型工业化发展先进企业”、“贵州百强企业”、“贵州制造业100强”等奖项及荣誉。
发行价格:
14.40
{"stockData":{"symbol":"600594","market":"SH","secType":"STK","nameCN":"益佰制药","latestPrice":4.33,"timestamp":1776150000000,"preClose":4.42,"halted":0,"volume":92379306,"delay":0,"changeRate":-0.0204,"floatShares":792000000,"shares":792000000,"eps":-0.2963,"marketStatus":"已收盘","change":-0.09,"latestTime":"04-14 15:00:00","open":4.35,"high":4.41,"low":4.22,"amount":397000000,"amplitude":0.043,"askPrice":4.34,"askSize":6558,"bidPrice":4.33,"bidSize":4232,"shortable":0,"etf":0,"ttmEps":-0.2963,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776216600000},"marketStatusCode":5,"adr":0,"adjPreClose":4.42,"symbolType":"stock","openAndCloseTimeList":[[1776130200000,1776137400000],[1776142800000,1776150000000]],"highLimit":4.86,"lowLimit":3.98,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":791927400,"isCdr":false,"pbRate":1.46,"roa":"--","roe":"--","epsLYR":-0.402,"committee":0.213122,"marketValue":3429000000,"turnoverRate":0.1167,"status":1,"floatMarketCap":3429000000},"requestUrl":"/m/hq/s/600594/wiki","defaultTab":"wiki","newsList":[{"id":"2627436971","title":"4月13日益佰制药(600594)龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2627436971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627436971?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:14","pubTimestamp":1776071651,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月13日公布的交易公开信息显示,益佰制药因有价格涨跌幅限制的日收盘价格跌幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第3次上榜。截至2026年4月13日收盘,益佰制药报收于4.42元,下跌8.11%,换手率15.36%,成交量121.66万手,成交额5.44亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300022341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0077","BK0060","600594","BK0028","BK0039","BK0070","BK0188","BK0096","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626124175","title":"每周股票复盘:益佰制药(600594)近5日4次登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2626124175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626124175?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:09","pubTimestamp":1775927349,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘,益佰制药报收于4.81元,较上周的4.7元上涨2.34%。本周,益佰制药4月7日盘中最高价报5.11元。益佰制药当前最新总市值38.09亿元,在中药板块市值排名51/67,在两市A股市值排名4099/5196。沪深交易所2026年4月7日公布的交易公开信息显示,益佰制药因有价格涨跌幅限制的日价格振幅达到15%的前五只证券,有价格涨跌幅限制的日换手率达到20%的前五只证券登上龙虎榜。此次是近5个交易日内第4次上榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0060","BK0070","600594","BK0077","BK0096","BK0039","BK0028","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626901038","title":"4月9日益佰制药(600594)涨停分析:新药获批、成本优化驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2626901038","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626901038?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:35","pubTimestamp":1775720140,"startTime":"0","endTime":"0","summary":"证券之星消息,益佰制药4月9日涨停收盘,收盘价5.06元。今日益佰制药涨停的可能因素有:注射用阿扎胞苷获批药品注册证书,视同通过一致性评价,加速上市并拓展血液肿瘤治疗领域;产品管线丰富化增强抗风险能力;成本费用同比下降18%,经营效率改善;叠加中药Ⅱ板块联动及近期连续获龙虎榜曝光,市场关注度提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900019355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0188","BK0039","600594","BK0077","BK0012","BK0060","BK0097","BK0028","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626261779","title":"股市必读:益佰制药(600594)4月8日收盘跌8.18%,主力净流出701.79万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2626261779","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626261779?lang=zh_cn&edition=full","pubTime":"2026-04-09 01:16","pubTimestamp":1775668571,"startTime":"0","endTime":"0","summary":"截至2026年4月8日收盘,益佰制药报收于4.6元,下跌8.18%,换手率17.87%,成交量141.55万手,成交额6.61亿元。来自龙虎榜上榜:益佰制药因日收盘价格跌幅偏离值达7%连续5个交易日登榜,市场波动加剧。交易信息汇总股价提醒4月8日益佰制药收盘报4.6元,跌8.18%,当日成交1.42亿元。资金流向4月8日主力资金净流出701.79万元,占总成交额1.06%;游资资金净流出833.48万元,占总成交额1.26%;散户资金净流入1535.27万元,占总成交额2.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900001056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0097","BK0012","BK0039","BK0077","BK0096","BK0070","BK0028","BK0060","600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625166936","title":"4月7日益佰制药(600594)龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2625166936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625166936?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:14","pubTimestamp":1775553284,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月7日公布的交易公开信息显示,益佰制药因有价格涨跌幅限制的日价格振幅达到15%的前五只证券,有价格涨跌幅限制的日换手率达到20%的前五只证券登上龙虎榜。此次是近5个交易日内第4次上榜。截至2026年4月7日收盘,益佰制药报收于5.01元,上涨6.6%,换手率23.86%,成交量188.94万手,成交额8.97亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0012","BK0070","BK0239","BK0028","BK0039","BK0096","BK0188","600594","BK0060","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625159086","title":"每周股票复盘:益佰制药(600594)近5日3次登上龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2625159086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625159086?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:07","pubTimestamp":1775322431,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,益佰制药报收于4.7元,较上周的3.84元上涨22.4%。本周,益佰制药4月3日盘中最高价报5.27元,股价触及近一年最高点。本周关注点交易信息汇总:益佰制药近5个交易日内第3次因日换手率达20%等情形登上龙虎榜。沪深交易所2026年4月2日公布的交易公开信息显示,益佰制药因日收盘价格涨幅偏离值达到7%及连续三个交易日内累计偏离值达20%的情形登上龙虎榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0039","BK0070","BK0060","BK0096","BK0097","600594","BK0077","BK0012","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624656402","title":"益佰制药(600594)披露股票交易异常波动公告,4月3日股价下跌2.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624656402","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624656402?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:12","pubTimestamp":1775207523,"startTime":"0","endTime":"0","summary":"贵州益佰制药股份有限公司于2026年4月3日发布《股票交易异常波动的公告》。公告显示,公司股票于2026年3月31日至4月2日连续三个交易日内日收盘价格涨幅偏离值累计超过20%,构成股票交易异常波动。公司自查并问询控股股东及实际控制人,确认不存在应披露而未披露的重大信息。董事会确认无应披露未披露事项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260403/32124840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0097","BK0096","BK0070","BK0188","BK0012","BK0039","BK0028","BK0239","600594","BK0077","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624157850","title":"BD+业绩双重炸裂,创新药多股涨停,黄金窗口期来了?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624157850","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624157850?lang=zh_cn&edition=full","pubTime":"2026-04-02 14:03","pubTimestamp":1775109822,"startTime":"0","endTime":"0","summary":"进入收获期","market":"sh","thumbnail":"https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4283048","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["GLDM","GDXY","159831","NUGT","GDX","DZZ","MGCmain","PALL","JDST","PHYS","BK4585","CEF","OUNZ","600488","000788","159934","UGL","GDXJ","GLD","GLL","IAU","600594","GDXU","159992","SGUmain","IAUM","JNUG","SGOL","QOmain","DUST","BK0188","DGP","000950","IAUI","SGCmain","XME","BK1191","GCmain","AAAU","GDXD","1OZmain","518880","02186","GLTR","02162","603222","BTGD","06978","300086","USG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624852188","title":"异动快报:益佰制药(600594)4月2日10点28分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2624852188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624852188?lang=zh_cn&edition=full","pubTime":"2026-04-02 10:35","pubTimestamp":1775097323,"startTime":"0","endTime":"0","summary":"证券之星4月2日盘中消息,10点28分益佰制药(600594)触及涨停板。其所属行业中药目前上涨。领涨股为益佰制药。该股为中药,医药,民营医院概念热股,当日中药概念上涨0.54%,医药概念上涨0.3%。4月1日的资金流向数据方面,主力资金净流入9361.38万元,占总成交额23.56%,游资资金净流出4223.56万元,占总成交额10.63%,散户资金净流出5137.82万元,占总成交额12.93%。近5日资金流向一览见下表:益佰制药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200011187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0039","BK0060","BK0239","BK0188","BK0012","BK0096","BK0097","BK0028","BK0070","600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624599429","title":"4月1日益佰制药(600594)龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2624599429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624599429?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:20","pubTimestamp":1775035225,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月1日公布的交易公开信息显示,益佰制药因有价格涨跌幅限制的日收盘价格涨幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月1日收盘,益佰制药报收于4.36元,上涨10.1%,换手率11.75%,成交量93.06万手,成交额3.97亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600594","BK0077","BK0188","BK0070","BK0028","BK0239","BK0097","BK0096","BK0012","BK0039","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623134773","title":"益佰制药(600594)披露获得注射用阿扎胞苷药品注册证书,3月30日股价上涨2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623134773","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623134773?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:38","pubTimestamp":1774863525,"startTime":"0","endTime":"0","summary":"截至2026年3月30日收盘,益佰制药报收于3.93元,较前一交易日上涨2.34%,最新总市值为31.12亿元。该股当日开盘3.83元,最高3.93元,最低3.82元,成交额达5461.37万元,换手率为1.77%。贵州益佰制药股份有限公司近日收到国家药品监督管理局核准签发的注射用阿扎胞苷《药品注册证书》,药品批准文号为国药准字H20263700,注册分类为化学药品4类,视同通过仿制药一致性评价。截至2024年12月31日,累计研发投入1,893.41万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000024370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600594","BK0097","BK0070","BK0188","BK0039","BK0012","BK0096","BK0077","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622519823","title":"益佰制药最新公告:获得注射用阿扎胞苷药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622519823","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622519823?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:01","pubTimestamp":1774609305,"startTime":"0","endTime":"0","summary":"益佰制药(600594.SH)公告称,公司近日收到国家药监局核准签发的注射用阿扎胞苷《药品注册证书》。该药品为化学药品4类,适用于治疗中危-2及高危骨髓增生异常综合征、慢性粒-单核细胞白血病及特定急性髓系白血病患者。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700041114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0060","BK0028","BK0097","BK0188","600594","BK0096","BK0239","BK0039","BK0077","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621082159","title":"股市必读:益佰制药(600594)3月23日收盘跌6.25%,主力净流出64.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621082159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621082159?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:51","pubTimestamp":1774299067,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘,益佰制药报收于3.45元,下跌6.25%,换手率2.34%,成交量18.54万手,成交额6547.97万元。交易信息汇总股价提醒3月23日益佰制药收盘报3.45元,跌6.25%,当日成交1854.1万元。该股已连续3日下跌。前10个交易日中,主力资金累计净流出4036.07万元,股价累计下跌12.11%;融资余额累计减少678.52万元,融券余量累计增加5.01万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400005257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0097","BK0039","BK0239","BK0070","BK0096","600594","BK0028","BK0012","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606232964","title":"每周股票复盘:益佰制药(600594)预计2025年扣非净亏损2.8亿至3.36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232964","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232964?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:41","pubTimestamp":1769280068,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,益佰制药报收于4.2元,较上周的4.07元上涨3.19%。本周,益佰制药1月23日盘中最高价报4.21元。公司公告汇总:因收入下降及商誉减值计提,益佰制药2025年业绩预亏。业绩披露要点益佰制药发布业绩预告,预计2025年全年扣非后净利润亏损2.8亿元至3.36亿元。公司公告汇总贵州益佰制药股份有限公司预计2025年度实现归属于母公司所有者的净利润为-34,200万元到-28,500万元,扣除非经常性损益后的净利润为-33,600万元到-28,000万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0060","BK0070","600594","BK0077","BK0096","BK0039","BK0028","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605170172","title":"益佰制药最新公告:预计2025年净利润亏损2.85亿元-3.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605170172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605170172?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:43","pubTimestamp":1768988602,"startTime":"0","endTime":"0","summary":"益佰制药(600594.SH)公告称,益佰制药发布2025年度业绩预告,预计归属于上市公司股东的净利润亏损2.85亿元-3.42亿元,将出现亏损。上年同期为亏损31,722万元。报告期内,公司主要产品销售减少导致收入下降,成本费用虽有所下降但仍高于收入;同时预计计提商誉减值准备11,000万元至13,200万元,进一步加剧亏损。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100029745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604492509","title":"每周股票复盘:益佰制药(600594)预计2025年净利为负","url":"https://stock-news.laohu8.com/highlight/detail?id=2604492509","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604492509?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:39","pubTimestamp":1768682347,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,益佰制药报收于4.07元,较上周的4.15元下跌1.93%。本周,益佰制药1月13日盘中最高价报4.26元。益佰制药当前最新总市值32.23亿元,在中药板块市值排名55/67,在两市A股市值排名4505/5183。业绩披露要点业绩预告益佰制药发布业绩预告,预计2025年全年归属净利润为负值,公司2025年度经营业绩将出现亏损。最终财务数据以公司正式披露的经审计后的2025年年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0188","BK0096","BK0012","BK0077","BK0239","BK0060","BK0097","BK0028","BK0070","600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602513273","title":"益佰制药:预计2025年全年归属净利润为负值,公司2025年度经营业绩将出现亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2602513273","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602513273?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:00","pubTimestamp":1768212036,"startTime":"0","endTime":"0","summary":"证券之星消息,益佰制药发布业绩预告,预计2025年全年归属净利润为负值,公司2025年度经营业绩将出现亏损。益佰制药2025年三季报显示,前三季度公司主营收入14.47亿元,同比下降15.59%;归母净利润-8656.26万元,同比上升48.83%;扣非净利润-8445.06万元,同比上升52.99%;其中2025年第三季度,公司单季度主营收入4.54亿元,同比下降16.87%;单季度归母净利润-6666.06万元,同比下降6.39%;单季度扣非净利润-5338.76万元,同比上升21.6%;负债率34.46%,投资收益-36.08万元,财务费用1596.77万元,毛利率60.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200025679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589339372","title":"益佰制药(600594)披露年度审计机构变更签字注册会计师公告,12月08日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589339372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589339372?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:52","pubTimestamp":1765187553,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘,益佰制药报收于4.19元,较前一交易日下跌1.41%,最新总市值为33.18亿元。公司近日发布公告称,因原第二签字注册会计师孙太宏从中证天通离职,现变更为肖缨接任公司2025年度财务报表和内部控制审计的第二签字注册会计师,第一签字注册会计师为李朝辉,质量控制复核人为邵富霞。肖缨自1995年注册为执业注册会计师,具备相应专业能力与独立性,近三年签署2家上市公司审计报告,未受到任何处罚。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800022630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0012","BK0188","BK0039","BK0097","BK0060","600594","BK0096","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586241475","title":"益佰制药(600594)股东窦启玲质押2100万股,占总股本2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586241475","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586241475?lang=zh_cn&edition=full","pubTime":"2025-11-27 18:39","pubTimestamp":1764239957,"startTime":"0","endTime":"0","summary":"证券之星消息,益佰制药11月27日公开信息显示,股东窦启玲向国泰海通证券股份有限公司合计质押2100.0万股,占总股本2.65%。质押详情见下表:截止本公告日,股东窦启玲已累计质押股份2100.0万股,占其持股总数的11.32%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700028389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0096","BK0028","BK0012","BK0077","BK0188","BK0060","BK0039","600594","BK0097","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586626312","title":"益佰制药(600594)披露增补公司独立董事议案获通过,11月26日股价上涨1.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586626312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586626312?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:42","pubTimestamp":1764168146,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘,益佰制药报收于4.23元,较前一交易日上涨1.93%,最新总市值为33.5亿元。该股当日开盘4.14元,最高4.4元,最低4.14元,成交额达1.02亿元,换手率为3.0%。近日,贵州益佰制药股份有限公司召开2025年第二次临时股东会,审议通过《关于增补公司独立董事的议案》。表决结果显示,议案获得通过,其中A股股东同意票占比99.2827%。北京市君致律师事务所对本次会议进行了见证并出具法律意见书,认为会议召集、召开程序及表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600039268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0012","BK0070","600594","BK0097","BK0077","BK0039","BK0028","BK0239","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776150298187,"stockEarnings":[{"period":"1week","weight":-0.0596},{"period":"1month","weight":0.1078},{"period":"3month","weight":0.0549},{"period":"6month","weight":0.0499},{"period":"1year","weight":0.3394},{"period":"ytd","weight":0.1106}],"compareEarnings":[{"period":"1week","weight":0.028},{"period":"1month","weight":-0.0261},{"period":"3month","weight":-0.0363},{"period":"6month","weight":0.0195},{"period":"1year","weight":0.2317},{"period":"ytd","weight":0.005}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贵州益佰制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"49116人(较上一季度增加6.22%)","perCapita":"16123股","listingDate":"2004-03-23","address":"贵州省贵阳市云岩区白云大道220-1号","registeredCapital":"79192万元","survey":" 贵州益佰制药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用洛铂、银杏达莫注射液、复方斑蝥胶囊、艾愈胶囊、心脉通胶囊、理气活血滴丸、丹灯通脑滴丸、疏肝益阳胶囊、妇炎消胶囊、葆宫止血颗粒、妇科调经滴丸、岩鹿乳康片、金莲清热泡腾片、金骨莲胶囊、心胃止痛胶囊、注射用瑞替普酶、科博肽。曾获得“中国医药制造业百强”称号、“中国AAA级信用企业”、“贵州省劳动关系和谐企业”、“中国大健康产业突出贡献奖”、“中国西部企业数字化转型优秀实践单位”、“年度品牌卓越企业”、“贵州企业100强”、“贵州省民营企业100强”、“贵州制造业企业100强”、“中华民族医药百强品牌企业”、“中国企业信用500强”、“贵州省制造业民营企业20强”、“中国医药工业百强企业”、“中国医药研发产业线最佳工业企业”、“中国医药工业最具投资价值企业”、“贵州省促进新型工业化发展先进企业”、“贵州百强企业”、“贵州制造业100强”等奖项及荣誉。","listedPrice":14.4},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益佰制药(600594)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益佰制药(600594)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益佰制药,600594,益佰制药股票,益佰制药股票老虎,益佰制药股票老虎国际,益佰制药行情,益佰制药股票行情,益佰制药股价,益佰制药股市,益佰制药股票价格,益佰制药股票交易,益佰制药股票购买,益佰制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益佰制药(600594)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益佰制药(600594)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}